Epidemiology of Heart Failure with Preserved Ejection Fraction

被引：92

作者：

Dhingra A. ^{[1
]}

Garg A. ^{[1
]}

Kaur S. ^{[2
]}

Chopra S. ^{[1
]}

Batra J.S. ^{[3
]}

Pandey A. ^{[4
]}

Chaanine A.H. ^{[5
]}

Agarwal S.K. ^{[5
,6
]}

机构：

[1] All India Institute of Medical Sciences, New Delhi

[2] Dayanand Medical College and Hospital, Ludhiana, Punjab

[3] Weill Cornell Medical College, New York, NY

[4] University of Texas Southwestern Medical Center, Dallas, TX

[5] Johns Hopkins University, 2020 E. Monument Street, Baltimore, 21287, MD

[6] Mount Sinai Health Systems, New York, NY

来源：

Current Heart Failure Reports | 2014年 / 11卷 / 4期

关键词：

Diastolic heart failure; Epidemiology; Preserved ejection fraction; Prevalence;

D O I：

10.1007/s11897-014-0223-7

中图分类号：

学科分类号：

摘要：

The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF. © 2014, Springer Science+Business Media New York.

引用

页码：354 / 365

页数：11

共 91 条

[1]

Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Et al., Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation, Circulation, 119, pp. 391-479, (2009)

[2]

Jessup M., Brozena S., Heart failure, N Engl J Med, 348, pp. 2007-2018, (2003)

[3]

Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., Et al., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), J Am Coll Cardiol, 38, pp. 2101-2113, (2001)

[4]

Go A.S., Mozaffarian D., Roger V.L., Benjamin E.J., Berry J.D., Blaha M.J., Et al., Heart disease and stroke statistics—2014 update: a report from the American Heart Association, Circulation, 129, 3, pp. e28-e292, (2014)

[5]

McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., Et al., ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J, 33, pp. 1787-1847, (2012)

[6]

Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection in a population-based study, N Engl J Med, 355, pp. 260-269, (2006)

[7]

Zile M.R., Gaasch W.H., Anand I.S., Haass M., Little W.C., Miller A.B., Et al., Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) trial, Circulation, 121, pp. 1393-1405, (2010)

[8]

Rosamond W.D., Chang P.P., Baggett C., Johnson A., Bertoni A.G., Shahar E., Et al., Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria, Circ Heart Fail, 5, 2, pp. 152-159, (2012)

[9]

Loehr L.R., Agarwal S.K., Baggett C., Wruck L.M., Chang P.P., Solomon S.D., Et al., Classification of acute decompensated heart failure: an automated algorithm compared with a physician reviewer panel: the Atherosclerosis Risk in Communities study, Circ Heart Fail, 6, 4, pp. 719-726, (2013)

[10]

Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, N Engl J Med, 355, pp. 251-259, (2006)

← 1 2 3 4 5 6 7 8 9 10 →